How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Veterinary Drugs for Companion Animals Market
- By Drug Type: Antibiotics, Antiparasitics, Vaccines, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Hormones and Synthetic Agents, Dermatologicals
- By Animal Type: Dogs, Cats, Small Mammals, Birds, Reptiles
- By Route of Administration: Oral, Injectable, Topical, Inhalation
- By Therapeutic Application: Infectious Disease Treatment, Pain Management, Endocrine Disorders, Gastrointestinal Disorders, Cardiovascular Disorders, Dermatological Conditions
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Antibiotics leads By Drug Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 287 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 16 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Veterinary Drugs for Companion Animals Market report
A complete, evidence-based study - 11 chapters and 120 sections covering market size, segmentation across 4 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Drug Type 6
Animal Type 5
Route of Administration 4
Therapeutic Application 6
Companies profiled
Zoetis Inc.
Boehringer Ingelheim GmbH
Elanco Animal Health Incorporated
Bayer AG (Animal Health Division)
Merck & Co.
Inc. (MSD Animal Health)
Ceva Santé Animale
Virbac S.A.
Vetoquinol S.A.
Pharmgate Animal Health
Dechra Pharmaceuticals PLC
Heska Corporation
+4 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Zoetis Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Boehringer Ingelheim GmbH
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Elanco Animal Health Incorporated
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bayer AG (Animal Health Division)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Merck & Co.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Inc. (MSD Animal Health)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Ceva Santé Animale
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Virbac S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Vetoquinol S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Pharmgate Animal Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Dechra Pharmaceuticals PLC
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Heska Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →IDEXX Laboratories Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Norbrook Laboratories Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Merial (now part of Boehringer Ingelheim)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Sumitomo Pharma Animal Health
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$1,966M by 2033 · 10.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Antibiotics30.1
- Antiparasitics14.2
- Vaccines15.9
- Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)15.2
- Hormones and Synthetic Agents12.0
- Dermatologicals12.7
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$294.8M → $646.9M · 10.3%
Europe$205.5M → $478.0M · 11.1%
Asia Pacific$187.6M → $398.3M · 9.9%
Latin America$116.1M → $258.1M · 10.5%
Middle East and Africa$89.3M → $188.1M · 9.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.332026
10.332027
10.342028
10.362029
10.362030
10.372031
10.392032
10.412033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Zoetis Inc.17.9
- Boehringer Ingelheim GmbH20.1
- Elanco Animal Health Incorporated9.0
- Bayer AG (Animal Health Division)5.7
- Merck & Co.8.0
- Inc. (MSD Animal Health)11.3
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Drug Type13.4%
Animal Type40.3%
Route of Administration33.6%
Therapeutic Application12.7%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.8
- Europe24.3
- Asia Pacific20.2
- Latin America13.1
- Middle East and Africa9.6
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Zoetis Inc. | 85 | 79 | 96 | 81 | 78 | 96 | 86 |
| Boehringer Ingelheim GmbH | 75 | 90 | 81 | 74 | 69 | 92 | 80 |
| Elanco Animal Health Incorporated | 69 | 84 | 77 | 75 | 69 | 63 | 73 |
| Bayer AG (Animal Health Division) | 60 | 68 | 79 | 77 | 68 | 61 | 69 |
| Merck & Co. | 73 | 53 | 72 | 65 | 64 | 69 | 66 |
| Inc. (MSD Animal Health) | 69 | 62 | 58 | 59 | 52 | 71 | 62 |
| Ceva Santé Animale | 63 | 56 | 44 | 53 | 44 | 48 | 51 |
| Virbac S.A. | 38 | 59 | 52 | 49 | 54 | 50 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Zoetis Inc.
- Boehringer Ingelheim GmbH
- Elanco Animal Health Incorporated
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Zoetis Inc. | ◐ | ◐ | ✓ | ✓ | ◐ | ✓ |
| Boehringer Ingelheim GmbH | ◐ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Elanco Animal Health Incorporated | ◐ | ◐ | ✓ | ◐ | − | ◐ |
| Bayer AG (Animal Health Division) | ◐ | ◐ | ✓ | ◐ | ✓ | ◐ |
| Merck & Co. | ◐ | − | ◐ | ✓ | − | ◐ |
| Inc. (MSD Animal Health) | − | ✓ | ◐ | − | ◐ | ◐ |
| Ceva Santé Animale | ◐ | ◐ | − | − | − | − |
| Virbac S.A. | − | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Zoetis Inc.86
2Boehringer Ingelheim GmbH80
3Elanco Animal Health Incorporated73
4Bayer AG (Animal Health Division)69
5Merck & Co.66
6Inc. (MSD Animal Health)62
7Ceva Santé Animale51
8Virbac S.A.50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Zoetis Inc.Boehringer Ingelheim GmbH
Challenger2
Strong scale, closing on the leaders.
Elanco Animal Health IncorporatedBayer AG (Animal Health Division)
Contender2
Focused players with pockets of strength.
Merck & Co.Inc. (MSD Animal Health)
Niche2
Specialists in a single segment or region.
Ceva Santé AnimaleVirbac S.A.
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Drug Type in North America, then scale across Veterinary Drugs for Companion Animals Market — a $163M beachhead inside a $2.48B market.
Beachhead (SOM)$163Mobtainable near-term
Serviceable (SAM)$1.01Breachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale5 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Antibiotics
Best fit — highest urgency & budget in Drug Type.
Economic buyer78 fit
Antiparasitics
Strong fit — clear ROI and a fast path to value.
End user67 fit
Vaccines
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Drug Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Animal Type & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel26%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Drug Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Veterinary Drugs for Companion Animals Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified43%
Sales qualified24%
Evaluation12%
Closed-won7%
$14.5KCAC
$77KLTV
5.3:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Veterinary Drugs for Companion Animals Market is a durable-growth opportunity — $10.1B by 2033, compounding at 8.1%.
TAM · 2025$5.43Btoday
TAM · 2033$10.1Bforecast
CAGR8.1%2027–2033
Cumulative$68.1Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$10.1BTotal addressable market
SAM$3.62BServiceable available market
SOM$770MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.1% CAGR
Demand compounds through 2033, outpacing GDP across Drug Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Drug Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$10.1BLarge & growingTAM by 2033 at 8.1% CAGR
$3.62BServiceable nowreachable with today’s model
$770MBeachhead winobtainable near-term share
16+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.91BBear5.3% CAGR
$10.1BBase8.1% CAGR
$13.0BBull10.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Animal Type optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Veterinary Drugs for Companion Animals Market — a $4.69B market by 2033. Plan: grow share from 8.3% to 13.4%.
Market size · 2033$4.69Btotal addressable
Market CAGR5.2%2027–2033
Target share13.4%from 8.3% today
Revenue ambition$629Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.3% | 13.4% | Ahead |
| Revenue | $398M | $629M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | At risk |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Ahead |
| Gross margin | 34.7% | 44.0% | On track |
| Customer retention | 89.5% | 93.1% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Drug Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Animal Type capability
A defensible second engine — invest in Animal Type to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Drug Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Animal Type
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $94M capacity & capability investment
- Greenlight bolt-on M&A in Animal Type
- Authorise North America expansion plan
- Fund R&D program for Drug Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskBehind
- Regulatory / policy changeAhead
- Execution & talentAt risk
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Veterinary Drugs for Companion Animals Market conversation — a $5.13B market you can size, segment and defend in minutes.
Market size · 2033$5.13Btotal opportunity
Growth6.5%CAGR to 2033
Addressable buyers1,086+accounts in scope
Typical ROI4.8×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Drug Type
Goal Grow share in Drug Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.8×return on cost, year one
< 4 mopayback period
$52K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
16+players profiled in this market
Coverage includes
Zoetis Inc.Boehringer Ingelheim GmbHElanco Animal Health IncorporatedBayer AG (Animal Health Division)Merck & Co.Inc. (MSD Animal Health)Ceva Santé AnimaleVirbac S.A.+8 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Veterinary Drugs for Companion Animals Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Veterinary Drugs for Companion Animals Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Veterinary Drug Residue Testing Service Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportVeterinary Drug Residues Testing Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportVeterinary Drug Residue Detector Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportVeterinary Drug Residue Detection Kit Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportVeterinary Drug Grade Fluralaner Active Pharmaceutical Ingredient Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportVeterinary DR Equipment Market
Market size, share, segmentation and regional forecast.
$2.5B market · 2025 base year
View reportVeterinary Doppler Ultrasound System Market
Veterinary Doppler Ultrasound System Market is valued at USD 215 Million in 2025 and is expecte…
$215M market · 2025 base year
View reportVeterinary Doppler Instrument Market
Market size, share, segmentation and regional forecast.
$5.2B market · 2025 base year
View reportVeterinary Doppler Detector Market
Market size, share, segmentation and regional forecast.
$2.7B market · 2025 base year
View reportVeterinary DNA Vaccines Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportVeterinary Disposable Medical Supplies Market
Market size, share, segmentation and regional forecast.
$1.3B market · 2025 base year
View reportVeterinary Diosmectite Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.